HIV-1-INFECTION

This early-stage study tests two experimental HIV vaccines for the first time in people. The goal is to see if they are safe and how well the immune system responds. Forty-five healthy adults without HIV, aged 18 to 55, will receive the vaccines and be followed for about 16 month…

This early-stage study tests whether two experimental HIV vaccines are safe and can trigger a strong immune response in healthy adults without HIV. The vaccines are designed to train the body to make special antibodies that can fight many types of HIV. The study involves 52 parti…

This early-stage study tests whether two experimental HIV vaccines (UVAX-1107 and UVAX-1197) are safe and can trigger an immune response in healthy adults without HIV. Twenty-five volunteers will receive injections and be monitored for about a year. The goal is to see if the vacc…

This study tests whether using simple, fast tests at the clinic can help people with HIV stick to their medication and keep the virus under control. About 539 people starting HIV treatment in South Africa will get either standard care or extra quick tests for drug levels and viru…

This study tests whether switching to a new two-drug combination pill (bictegravir/lenacapavir) is as safe and effective as staying on the standard three-drug pill (Biktarvy) for people with HIV-1 whose virus is already under control. About 577 participants who have been on Bikta…

This study tests a three-in-one pill (Bictegravir/Emtricitabine/Tenofovir Alafenamide) for HIV-1 in children and teens aged 2 to 17. The goal is to see how the body processes the drug, confirm the right dose, and check safety. Participants take the pill once daily, and researcher…

This study tests whether people with well-controlled HIV can switch from a daily pill (B/F/TAF) to a once-weekly pill (Islatravir/Lenacapavir) and keep the virus suppressed. About 600 adults who have had undetectable HIV for at least 6 months will take either the weekly or daily …

This study tests whether a once-weekly pill (islatravir + lenacapavir) can keep HIV under control in people whose virus is already suppressed by daily medication. About 142 adults with HIV-1 who have been on a stable daily regimen for at least 24 weeks will switch to the weekly p…

This study tests a new long-acting injectable drug, lenacapavir, in people with HIV that has become resistant to many current medications. The goal is to see if adding this drug to their existing treatment can lower the amount of virus in their blood. The study involves 72 adults…

This study looks at whether older adults (60+) with HIV can safely switch from their current medication (B/F/TAF) to a simpler two-drug pill (DTG/3TC). About 240 participants in Kenya will be followed for 96 weeks to see if the new pill keeps the virus under control. The goal is …

This study looks at whether switching to a combination of bictegravir and lenacapavir (two drugs) works as well as staying on a more complex HIV treatment regimen. About 689 adults with HIV-1 who have the virus under control will take part. The goal is to see if the simpler regim…

This early-stage study tests a single dose of a new long-acting antibody in 20 people with HIV who are not on regular medication. The goal is to check safety and see if the antibody can lower the amount of virus in the blood. Results will help design future studies for both HIV t…

This study tests if people with HIV whose virus is already controlled can switch to a once-weekly pill (islatravir/lenacapavir) instead of their daily medication. About 600 adults will either switch to the weekly pill or stay on their current daily treatment. The main goal is to …

This study tests whether adults with HIV who are already undetectable on a three-drug regimen can safely switch to a new two-drug pill (doravirine/islatravir) taken once daily. About 514 participants will be randomly assigned to either switch or stay on their current medication. …

This study tests whether a combination of two lab-made antibodies (teropavimab and zinlirvimab) plus the drug lenacapavir, given as injections every 6 months, can keep HIV under control in adults whose virus is already suppressed by daily pills. About 83 participants will either …

This study tests a new once-daily pill (doravirine/islatravir) for people with HIV who have never taken HIV medication before. About 537 participants will receive either the new pill or a standard combination pill to see how well they control the virus and how safe they are. The …

This study tests whether switching to a new once-daily combination pill (Doravirine/Islatravir) is as safe and effective as staying on current HIV medications. About 550 adults with HIV-1 who have undetectable virus levels will take either the new pill or continue their usual tre…

This study looks at the long-term safety of a once-daily pill combining two drugs (Doravirine and Islatravir) for people with HIV-1. It involves 2,000 participants who already took this medication in earlier studies and are continuing it. The main goal is to track serious side ef…

This study tests if a new once-weekly pill (GS-1720 plus GS-4182) can keep HIV under control as well as the daily medication Biktarvy. About 675 adults with already-suppressed HIV will switch to the weekly pill or stay on Biktarvy. The goal is to see if the weekly option is safe …

This study tests whether giving two lab-made antibodies can safely help control HIV when people stop their regular antiretroviral therapy for a short time. About 32 adults with HIV in Sub-Saharan Africa will receive either the antibodies or a placebo by IV infusion. The goal is t…

This study tests whether pomalidomide, a drug used for certain cancers, can help people with HIV control the virus better. It involves 32 adults with well-controlled HIV who will temporarily stop their regular HIV medication to see if pomalidomide keeps the virus at bay. The main…

This early-phase study tests the safety and how the body handles a single-dose HIV prevention drug (B/F/TAF) in 16 full-term newborns who were exposed to HIV at birth but are not infected. The goal is to see if the drug is safe and how it moves through the babies' bodies, helping…

This study tests the 9-valent HPV vaccine in 700 men living with HIV to see if it can prevent long-lasting oral HPV infections that can lead to cancer. Participants receive the vaccine or a placebo and are followed for up to four years. The goal is to stop HPV types linked to thr…

This study looks at how to best roll out a brief alcohol counseling program in HIV clinics across Vietnam. The goal is to reduce unhealthy drinking, which can lead to risky behaviors and HIV spread. Over 3,200 people living with HIV and clinic staff are taking part. One group of …

This study measures two markers (CD32a and X) on immune cells from 48 adults with HIV who have had undetectable virus for at least 2 years on treatment. The goal is to see if these markers relate to the amount of hidden HIV DNA in cells. No new treatment is given; the study only …

This study looks at whether a simple, home-based walking program can help improve blood sugar, cholesterol, and body measurements in people living with HIV who also have metabolic syndrome. About 50 adults, with or without HIV, will gradually increase their walking over six month…

This study looks at 40 people with HIV to see if a common drug called tenofovir causes more immune activation and helps the virus hide in the body. Researchers will compare those on tenofovir-containing treatments to those on other regimens. The goal is to understand how differen…

This study is a long-term safety follow-up for 11 HIV patients who previously received a gene therapy called Cal-1. The goal is to watch for any delayed side effects from the treatment and to see how long the modified cells survive in the body. Participants are not receiving new …